1Homko C, Deluzio A,Jimenez C, et al. Comparison of insulinaspart and 1 ispro : pharmacokinetic and metabolic effects. Diabetes Care, 2003,26 (7) :2027.
5Bretze IRG,Amolds S,Medding J,et al. A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human prem ix insulin (70/30) in patients with type 2 diabetes. Diabetes- Care, 2004,27 ( 5 ) : 1023-1027.
6Monnier L,Lapinsk HI,Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type2 diabetic patients : variations with increasing levels of HbAlc. Diabetes Care,2003,26(3) :881-885.
二级参考文献10
1Juhl CB, Porksen N, Hollingdal M, et al. Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequencv. Diabetes Care 2000; 23: 675 - 81.
2Weyer C. Bpgardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-94.
3Hollingdal M, Juhl CB, Pincus SM, et al. Failure of physiological plasma glucose excursions to entrain high-frequency pulsatile insulin secretion in type 2 diabetes. Diabetes 2000 ;49:1334 - 40.
4Kahn SE. The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab2001 ;86: 4047 - 58.
5Brownlee MA. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2004; 53 (Suppl 2): 6.
6Alvarsson M, Sundkvist G, Lager I, et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003;26: 2231 - 37.
7Ilkova H, Glaser B, Tunckale A, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997;20:1353 - 6.
8Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.Diabetes 2002;51:2796-803.
9Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic β-cell function of subjects with type 2 diabetes. Diabetes Care2004 ;27: 2585 - 89.
